The gut–bone axis: implications of gut hormone-based therapies for bone health
Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel increases in serious and potentially fatal comorbidities, particularly type 2 diabetes and atherosclerotic cardiovascular disease. This trajectory emphasises the urgent need to address this growing health crisis. Cardiometabolic diseases can have detrimental effects on bone health, leading to fractures, morbidity and mortality, and reduced quality of life.1 Despite these known relationships, bone health is often underestimated and overlooked in this context.
